Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial.

Steffen Desch,Jochen Wöhrle,Rainer Hambrecht,Harald Rittger,Ralf Birkemeyer,Bernward Lauer,Petra Neuhaus,Oana Brosteanu,Peter Sick,Matthias Pauschinger,Sebastian Kerber,Klaus Kleinertz,Suzanne de Waha,Ingo Eitel,Gerhard Schuler,Holger Thiele

Journal of the American College of Cardiology（2013）

引用 30|浏览16

暂无评分

摘要

To the Editor: In patients with ST-segment elevation myocardial infarction (STEMI), direct intracoronary as compared with standard intravenous bolus administration of the glycoprotein IIb/IIIa receptor antagonist abciximab acutely causes higher local drug concentrations, greater glycoprotein IIb/

查看译文

关键词

myocardial infarction,st-segment st-segment elevation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要